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Background: Minimal persistent inﬂammation (MPI) contributes to hyperreactivity in allergic rhinitis.
However, little is known regarding whether pre-onset activation of eosinophils and mast cells is present
or not in Japanese cedar pollinosis (JCP). Furthermore, a prophylactic effect of intranasal corticosteroids
on such MPI in JCP has not been investigated.
Methods: We designed a double-blinded, randomized, placebo-controlled, crossover trial. Twenty pa-
tients with JCP were examined outside the pollen season (UMIN000008410). Nasal provocation with
paper discs containing extracts of Japanese cedar pollen was performed once a day for 3 consecutive
days. Onset of nasal symptoms was monitored over 15 min after each provocation. The levels of
eosinophil cationic protein (ECP) and tryptase in nasal secretions were examined. Fluticasone furoate
nasal spray or placebo treatment was started one day before the ﬁrst provocation.
Results: In the placebo group, 25% of the patients showed onset of nasal symptoms following provoca-
tion on the ﬁrst day. In addition, 75% and 68% of the patients showed symptom onset on the second and
third day of provocation, respectively. After the ﬁrst provocation, the levels of ECP and tryptase in nasal
secretions were signiﬁcantly increased. These increases were seen not only in symptomatic but also in
asymptomatic subjects in response to provocation, and the levels were similar between these subjects.
Prophylactic treatment with ﬂuticasone signiﬁcantly suppressed the increase in nasal ECP and tryptase
associated with repeated provocations.
Conclusions: These results suggest that pre-onset activation of eosinophils and mast cells is present in
experimental JCP, and that prophylactic treatment with intranasal corticosteroids has the potential to
control such activation.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In allergic rhinitis (AR), minimal persistent inﬂammation (MPI)
is characterized by an inﬂux of inﬂammatory cells such as eosino-
phils and neutrophils into the nasal mucosa without the onset of
nasal symptoms following exposure to low levels of allergen.1 MPIology-Head & Neck Surgery,
entistry and Pharmaceutical
.
kano).
ety of Allergology.
rgology. Production and hosting by Elsewas originally described after the end of symptoms in both
perennial and seasonal allergic rhinitis.2,3 It has been suggested
that MPI is also present in the initial dispersion of pollen prior to
onset of symptoms, which contributes to hyperreactivity and sub-
sequently to onset of full-scale symptoms; however, the precise
characterization and clinical implication of this “pre-onset” MPI
remains to be elucidated.1,3,4
Prophylactic, in other words early interventional or initial,
treatment starting immediately after pollen release or the onset of
symptoms is recommended in patients who annually experience
substantial symptoms of pollen-induced seasonal allergic rhinitis.5
Placebo-controlled studies conﬁrmed that anti-histamines, anti-
leukotrienes and intranasal corticosteroids (INS) are effective forvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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prophylactic treatment with INS has been shown to delay onset
and reduce symptom severity.1,7e10 For example, we reported that
prophylactic treatment with mometasone furoate nasal spray did
not induce the substantial onset of pollinosis, whereas placebo
treatment did, in the relatively low pollen dispersal season in
Japanese cedar pollinosis (JCP), the most prevalent seasonal
allergic rhinitis in Japan.9 In addition, we have recently demon-
strated that this prophylactic treatment signiﬁcantly delayed the
onset of symptoms and alleviated symptom severity compared not
only with placebo but also with post-onset treatment with
mometasone in the relatively high pollen dispersal season.10 One
of the bases of prophylactic treatment is the control of pre-onset
MPI; however, little is known regarding how INS controls pre-
onset MPI.
In the present study, we sought to determine whether pre-onset
activation of eosinophils and mast cells exists in experimental JCP.
In addition, the efﬁcacy of INS for this pre-onset activation was
investigated. These results provide a basis for understanding the
clinical implications of INS for prophylactic treatment in seasonal
AR.Methods
Patients
Twenty patients with JCP, between the ages of 22 and 52 years
(mean 35.3 ± 10.4 years; 6 males and 14 females) were enrolled. All
the patients had at least a 2-year history of JCP and were asymp-
tomatic out of the pollen season. Sensitization to Japanese cedar
pollen was assessed by a skin prick test. Patients were excluded
from the study if they had: (a) sensitization to house dust mite
assessed by a skin prick test, (b) concomitant sinonasal disease that
could potentially affect the outcome of the trial (e.g., nasal polyps,
rhinosinusitis, nasal septum deviation); (c) rhinitis medicamentosa
and non-infectious, non-allergic rhinitis; (d) cedar pollen-speciﬁc
immunotherapy; (e) sinonasal surgery including laser vapor-
ization of inferior turbinates within 1 year; (f) medication with
anti-allergic drugs including antihistamines, chromones, gluco-
corticoids and decongestants within 2 weeks of study initiation; (g)
hypersensitivity to ﬂuticasone furoate nasal spray; (h) systemic
infection including mycosis; or (i) were pregnant and breastfeed-
ing. Prior to the study initiation, we estimated the sample size that
would be required based on themean and standard deviation in the
groups reported in our previous studies.9,10Study design
The study was a single-center, double-blinded, randomized,
placebo-controlled, crossover trial that was carried out in August,Fig. 1. Study design. Subjects received a nasal provocation test with control discs (C) followe
placebo spray was given to the subjects starting from one day prior to the ﬁrst provocationoutside the Japanese cedar pollen season (Fig. 1). Allocation
concealment was granted by the central registry and computer-
generated block randomization. The control nasal provocation,
followed by active allergen provocation with a 15 min interval,
was given for 3 consecutive days. The allergen provocation test
was performed by placing two paper discs (Torii Pharmaceutical,
Tokyo, Japan) containing the Japanese cedar pollen extract that is
used for skin scratch tests (14.7 mg in 5 ml per disc, Torii), to the
surface of the bilateral inferior turbinates for 5 min. Control discs
contained 5 ml of the control solution used for the scratch test
(Torii Pharmaceutical). After 5 min, the discs with adsorbed nasal
secretions were removed, placed into a 1.5 ml micro test tube
(Eppendorf AG, Hamburg, Germany), and stored at 80 C until
assayed. The subjects were monitored for 15 min as to whether
they showed an onset of nasal symptoms such as sneezing,
itching, rhinorrhea and nasal congestion in response to nasal
provocation. Fluticasone furoate nasal spray (FFNS: 55 mg per
nostril once a day in the morning) or the placebo spray was
administered to the subjects starting from one day prior to the
ﬁrst provocation. The placebo spray provided by GlaxoSmithKline
K.K. had a white-colored lid and trigger. The lid and trigger of the
FFNS bottle, which were initially cyan-colored, were changed to
white to ensure that both FFNP and placebo spray appeared the
same. This treatment was continued until the third provocation (4
days in total). Wash-out periods of 2 weeks were instituted be-
tween the treatments (Fig. 1). The study was approved by the
Institutional Review Board of Okayama University Graduate
School of Medicine, Dentistry and Pharmaceutical Sciences (Rinri-
1436), and is registered in UMIN (UMIN000008410). Prior to
participation in the study, all patients provided written informed
consent.Measurement of nasal ECP and tryptase
The discs were soaked overnight at 4 C in 0.8 ml of Dul-
becco's phosphate buffered saline (Invitrogen, Grand Island, NY,
USA) with gentle rotation. Levels of ECP and tryptase were
determined by ImmunoCAP ECP and ImmunoCAP tryptase,
respectively (Phadia, Uppsala, Sweden). The detection limit of
the assay for ECP and tryptase was 2 ng/ml and 1 ng/ml,
respectively.Statistical analysis
Values are expressed as the median value. A non-parametric
ManneWhitney U test and Fisher's exact probability test were
used to compare the data between groups, while the Wilcoxon
signed rank test was used for analysis within the groups. Statistical
analyses were performed using SAS (Statistical Analysis System)
version 9.2, with P < 0.0.5 considered to be signiﬁcant.d by allergen discs (A) for 3 consecutive days. Fluticasone furoate nasal spray (FFNS) or a
. After wash-out for 2 weeks, a crossover trial was performed.
Fig. 3. Levels of nasal tryptase following repeated nasal provocation with Japanese
cedar pollen extract in subjects treated with placebo. Control discs (C) followed by
allergen discs (A) were placed on the surface of the bilateral inferior turbinates for
5 min with a 15 min interval. This provocation was given for 3 consecutive days. Levels
of tryptase in nasal secretions adsorbed to the discs were determined. The rectangle
includes the range from the 25th to the 75th percentiles; the horizontal line indicates
the median, and the vertical line indicates the range from the 10th to the 90th per-
centiles. P values were determined using the Wilcoxon signed rank test.
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Release of ECP and tryptase in nasal secretions following allergen
provocation in the placebo treatment group
In the groups treated with placebo, the levels of ECP in nasal
secretions extracted from the paper discs remained unchanged
5 min after each provocation. However, the baseline levels of ECP
determined in the control disc of the second day (P ¼ 0.003) and
third day (P ¼ 0.004) provocations were signiﬁcantly increased
compared to the baseline ECP on the ﬁrst day of provocation,
suggesting that exposure to Japanese cedar pollen induced release
of ECP (Fig. 2).
A signiﬁcant increase in the levels of tryptase was seen 5 min
after the ﬁrst day provocation (P ¼ 0.008). However, unlike the ECP
response, the tryptase levels returned to the baseline prior to the
active provocation on the second day. The tryptase response on the
second and third day provocations was similar to that on the ﬁrst
day of provocation (Fig. 3).
Onset of nasal symptoms after allergen provocation for 3
consecutive days in the placebo treatment group
Fifteen minutes after the ﬁrst provocation, 5 out of 20 (25%)
patients treated with placebo showed an onset of nasal symptoms.
In addition, 15 (75%) and 14 (68%) patients showed symptom onset
after the second and third day provocation, respectively. No sig-
niﬁcant differences in age, sex, a history of smoking or complica-
tions including bronchial asthma, aspirin intolerance, perennial
rhinitis, atopic dermatitis, food allergy and drug allergies were
found between patients showing positive (symptomatic, group A,
n ¼ 5) and negative (asymptomatic, group B, n ¼ 15) response to
the ﬁrst allergen provocation (Table 1).
Levels of ECP and tryptase after the ﬁrst day provocation in
symptomatic and asymptomatic patients
We next focused on analysis of ECP and tryptase levels in the
patients that showed a negative or a positive response to the ﬁrstFig. 2. Levels of nasal ECP following repeated nasal provocation with Japanese cedar
pollen extract in subjects treated with placebo. Control discs (C) followed by allergen
discs (A) were placed on the surface of the bilateral inferior turbinates for 5 min with a
15 min interval. This provocation was given for 3 consecutive days. Levels of ECP in
nasal secretions adsorbed to the discs were determined. The rectangle includes the
range from the 25th to the 75th percentiles; the horizontal line indicates the median,
and the vertical line indicates the range from the 10th to the 90th percentiles. P values
were determined using the Wilcoxon signed rank test.day provocation. Nasal ECP and tryptase levels in the control and
active (pollen) disc on the ﬁrst, second, and third day in each group
were shown in Table 2. Levels of ECP in the control disc on the
second day were similar between the groups (Fig. 4A, P ¼ 0.861). In
addition, signiﬁcant elevation in the levels of ECP was seen in
asymptomatic patients on day 2 compared to day 1 (Fig. 4B,
P ¼ 0.013). Levels of tryptase in the allergen disc on the ﬁrst day
were also similar between symptomatic and asymptomatic pa-
tients (Fig. 5A, P ¼ 0.364). In addition, signiﬁcant elevation in the
levels of tryptase was seen in the allergen discs of asymptomatic
patients compared to the control discs (Fig. 5B, P ¼ 0.012).Effect of prophylactic treatment of FFNS on ECP and tryptase release
Prophylactic treatment with FFNS did not inhibit the release of
ECP on the ﬁrst day provocation as compared with the placebo
treatment due to a small release even in the placebo treatment.
However, a signiﬁcant decrease in ECP levels was seen in control
discs on the second (P ¼ 0.004) and third (P < 0.001) day provo-
cation in FFNS treatment as compared with the placebo treatment
(Fig. 6). Signiﬁcant inhibition of tryptase levels by FFNS treatment
was also seen in allergen discs on the second (P ¼ 0.034) and third
(P ¼ 0.023) day provocation (Fig. 7). The effect of the treatmentTable 1
Demographic characteristics of patients showing symptomatic (group A) and
asymptomatic (group B) response to the ﬁrst provocation.
Group A Group B
Number 5 15
Age (mean ± SD) 33.8 ± 6.6 35.4 ± 11.3
Sex (male/female) 1/4 5/10
History of smoking 0/5 0/15
Complications Bronchial asthma 0/5 0/15
Aspirin intolerance 0/5 0/15
Perennial rhinitis 0/5 1/15
Atopic dermatitis 2/5 4/15
Food allergy 0/5 0/15
Drug allergies 1/5 0/15
Results were shown as mean ± standard deviation.
Table 2
Median levels of nasal ECP and tryptase in the control (C) and active (A) pollen disc
on the ﬁrst, second, and third day in two groups of placebo-treated patients showing
symptomatic (group A) and asymptomatic (group B) response to the ﬁrst
provocation.
Day 1 Day 2 Day 3
C A C A C A
ECP
(ng/ml)
Group A
(n ¼ 5)
Placebo 2.46 0 20.43 18.32 28.38 12.04
FFNS 0 0 4.65 0 0 1.07
P value 0.109 0.180 0.068 0.465 0.109 0.109
Group B
(n ¼ 15)
Placebo 0 2.24 28.27 28.20 40.99 26.84
FFNS 0 3.00 4.00 3.20 0 3.33
P value 0.441 0.059 0.023 0.023 0.001 0.015
Typtase
(ng/ml)
Group A
(n ¼ 5)
Placebo 0 0 0 0 0 0
FFNS 0 0 0 0 0 1.31
P value e 0.180 e 0.180 0.317 0.285
Group B
(n ¼ 15)
Placebo 0 1.35 0 2.42 0 1.40
FFNS 0 0 0 0 0 0
P value e 0.038 0.180 0.074 0.655 0.009
Effect of the treatment with FFNS was also shown. P values were determined using
Wilcoxon's signed rank test.
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third provocation in each group (A and B) was shown in Table 2. The
onset rate of nasal symptoms was not signiﬁcantly different be-
tween placebo and FFNS treatment in the group of patients (n ¼ 5)
showing positive response to the ﬁrst provocation (P ¼ 0.083,
P ¼ 0.222 and P ¼ 0.444 at the ﬁrst, second and third provocation,
respectively). Similar ﬁndings were seen in the group of patients
(n ¼ 15) showing negative response to the ﬁrst provocation
(P ¼ 0.112, P ¼ 0.231 and P ¼ 0.233 at the ﬁrst, second and third
provocation, respectively).
Discussion
In the present study, we demonstrated that ECP and tryptase
were released into nasal secretions not only in symptomatic but
also in asymptomatic patients with JCP following a single allergen
provocation outside the pollen season. In addition, treatment with
ﬂuticasone that was started one day prior to the ﬁrst provocation
signiﬁcantly suppressed the increase in nasal ECP and tryptase that
occurred with repeated provocations. We and others have reported
that prophylactic treatment with INS is effective for pollinosis.7,9,10Fig. 4. Nasal ECP levels following a single allergen provocation. (A) Nasal ECP levels in the
response to the ﬁrst provocationwere compared. The bar represents the median value. P valu
the control disc between the ﬁrst and second day were determined in patients with a negati
determined using Wilcoxon's signed rank test.The present results suggest that the prophylactic effect of INS on
pollinosis is mediated by the suppression of pre-onset activation of
eosinophils and mast cells.
In contrast to the originally described MPI that is seen after the
end of symptoms, little is known about “pre-onset” MPI and its
regulation. Ricca et al. were the ﬁrst to demonstrate increases in
eosinophils, neutrophils and ICAM-1 expression prior to the initial
onset of nasal symptoms, which were clinically evident in patients
with birch pollinosis only after pollen counts increased dramati-
cally.3 Several studies investigated MPI in seasonal allergic rhinitis
using a nasal provocation test with allergen.4,11 Juliusson et al.
demonstrated an increase in eosinophils and mast cells in asymp-
tomatic patients with strictly seasonal allergic rhinitis to timothy
pollen following a single allergen provocation; however, all pa-
tients displayed nasal symptoms following the provocation.11
Roquet et al. demonstrated that although 7 days of exposure to
birch pollen allergen at low doses outside the pollen season caused
few symptoms, it produced increased ECP but not histamine in
lavage ﬂuid from patients with seasonal allergic rhinitis.4 Our re-
sults were consistent with this report by Roquet et al. in terms of
ECP release by asymptomatic patients, and further demonstrated
that pre-onset activation of eosinophils and mast cells can be
induced even after a single allergen provocation.
On the other hand, unlike the observation by Roquet et al. in
which no or minimal symptoms were observed, we found that 25%
of the patients showed an onset of nasal symptoms after a single
provocation. These different results may be due to the difference in
the allergen dose used for provocation. The allergen dose set by
Rousquet et al. was approximately 1/100 of the cumulative dose
until symptoms of itching and sneezing occurred for each indi-
vidual.4 We used two paper discs containing a Japanese cedar
pollen extract that is used for skin scratch tests (14.7 mg of protein in
5 ml per disc) for provocation. Our dose may be higher than that set
by Roquet et al.
In the present study, nasal ECP and tryptase were monitored as
speciﬁc markers for the activation of eosinophils and mast cells,
respectively.12 Previous studies reported that elevation of nasal ECP
levels is mainly seen in the late-phase response and is sometimes
seen in the early-phase response following allergen provoca-
tion.13e16 The present study showed that a signiﬁcant elevation of
nasal ECP was seen at 24 h but not at 5 min after a single allergencontrol disc on the second day in patients with negative (n ¼ 15) or positive (n ¼ 5)
es were determined using the ManneWhitney U test. (B) Changes in nasal ECP levels in
ve response to the ﬁrst provocation. The bar represents the median value. P values were
Fig. 5. Nasal tryptase levels following a single allergen provocation. (A) Nasal tryptase levels in the allergen disc on the ﬁrst day were compared between patients with a negative
(n ¼ 15) or a positive (n ¼ 5) response to the ﬁrst provocation. The bar represents the median value. P values were determined using the ManneWhitney U test. (B) Changes in nasal
tryptase levels between the control and allergen discs on the ﬁrst day were determined in asymptomatic patients in response to a single provocation. The bar represents the median
value. P values were determined using Wilcoxon's signed rank test.
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phase response in this experimental model. This result is similar to
the report by Raulf-Meimsoth et al.15 They measured nasal ECP at
30min, 2, 6 and 24 h after nasal provocation and found a signiﬁcant
elevation of nasal ECP that started at 2 h after provocation and
lasted for 24 h. Together with the ﬁnding that the elevation of nasal
ECP was seen not only in symptomatic but also in asymptomatic
subjects, these results suggest a pre-onset activation of eosinophils
following exposure to Japanese cedar pollen.
On the other hand, despite it can be speculated that the accu-
mulation of eosinophils is enhanced by repeated stimulation with
allergen, the reason why the baseline levels of ECP between the
second day and the third day was not signiﬁcant (P ¼ 0.554) is not
clear. Future evidences should be provided whether not only the
activation but also the accumulation of eosinophils in nasal secre-
tions is induced in this experimental model.
Tryptase is a neutral protease that is selectively released from
mast cells.17 Previous studies demonstrated that nasal tryptase in
nasal secretions or lavages are increased in the early phase but notFig. 6. Effect of prophylactic treatment with ﬂuticasone furoate on nasal ECP levels followi
received the ﬂuticasone furoate nasal spray (FFNS) or the placebo spray. ECP levels in nas
treatment. The bar represents the median value. P values were determined using Wilcoxonin the late phase response following nasal provocation with
allergens.14e16 The present study showed that a signiﬁcant eleva-
tion of nasal tryptase was seen at 5 min but not at 24 h after a single
allergen provocation. This result is consistent with the previous
reports.14e16 Similar to ECP, the elevation of nasal tryptase was seen
not only in symptomatic but also in asymptomatic subjects, sug-
gesting that an induction of early-phase minimal inﬂammation
with mast cells occurs following exposure to Japanese cedar pollen.
Mast cells also contribute to late-phase responses through upre-
gulation of cytokines and chemokines including GM-CSF, RANTES,
eotaxins and TRAC.18 Although a speciﬁc marker of mast cell acti-
vation in late-phase responses has not been available, future
investigation should determine whether mast cells contribute to
“pre-onset” persistent inﬂammation in pollinosis.
The present study demonstrated that repeated nasal allergen
provocations increased the rate of onset of nasal symptoms. This
result is consistent with previous reports that demonstrated that
repeated allergen provocations during out of pollen season
decrease the threshold for nasal symptoms in pollinosis.19,20 On theng repeated allergen provocations. One day prior to the ﬁrst provocation, the subjects
al secretion adsorbed to the control discs were compared between FFNS and placebo
's signed rank test.
Fig. 7. Effect of prophylactic treatment with ﬂuticasone furoate on nasal tryptase levels following repeated allergen provocations. The subjects received FFNS or the placebo spray
one day prior to the ﬁrst provocation. Tryptase levels in nasal secretions adsorbed to the allergen discs were compared between FFNS and placebo treatment. The bar represents the
median value. P values were determined using Wilcoxon's signed rank test.
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existence of MPI characterized by the activation of eosinophils and
mast cells prior to the onset of nasal symptoms in repeated allergen
provocation tests. Priming effect was originally called by Connell
that the number of allergen required to elicit a positive nasal
symptomwas reduced by 10- to 100-fold when a second challenge
was repeated to the following day.21 Strictly speaking, although
priming effect and pre-onset activation of eosinophils and mast
cells share common pathological characteristics, they are different
in terms of the presence or absence of nasal symptoms.
Intranasal glucocorticosteroids (INS) are the most effective
drugs for controlling AR-caused inﬂammation.22 It is well known
that INS suppress the release of ECP and tryptase into nasal se-
cretions.23,24 For example, Di Lorenzo et al. showed that treatment
with ﬂuticasone propionate aqueous nasal spray signiﬁcantly re-
duces the levels of ECP and tryptase in nasal lavage whereas pla-
cebo treatment does not.23 In terms of prophylactic treatment with
INS, Ahlstrom-Emanuelsson et al. showed that prophylactic treat-
ment with budesonide signiﬁcantly suppresses histamine-induced
release of ECP and tryptase in nasal saline lavage.24 We also re-
ported that prophylactic treatment with mometasone furoate
suppressed the levels of ECP in nasal secretion as compared with
placebo treatment during the peak season of Japanese cedar pollen
in patients with JCP.9 The anti-inﬂammatory effect of glucocorti-
coids is due to the down-regulation of pro-inﬂammatory genes via
several mechanisms including an effect on the proteineprotein
interactions that sequester protein kinase A and CREB-binding
protein from NF-kB.25,26 The interaction between NF-kB, CREB,
and the CREB-binding protein leads to the acetylation of chromatin
and the subsequent transcription of proinﬂammatory genes, such
as the genes encoding cytokines, inﬂammatory enzymes, adhesion
molecules and inﬂammatory receptors.27 Thus prophylactic use of
INS may be more effective than post-onset use in controlling
inﬂammation where the activity of NF-kB is relatively lower than
that in the peak pollen season. In fact, Table 2 showed that signif-
icant reductions in the levels of ECP and tryptase were seen by the
treatment with FFNS as compared with placebo in asymptomatic
patients (Group B) but not symptomatic patients (Group A). How-
ever, this may be due to the small number of patients in Group A
(n ¼ 5).
In conclusion, activation of eosinophils and mast cells was seen
in asymptomatic patients with JCP after a single allergen provoca-
tion, and prophylactic use of INS was effective in inhibiting thisactivation. These results suggest that the prophylactic effect of INS
on JCP is mediated by the suppression of pre-onset activation of
eosinophils and mast cells. Future investigation should consider
whether other inﬂammatory cells including lymphocytes and
dendritic cells, as well as constitutive cells including epithelial cells
and ﬁbroblasts, contribute to pre-onset activation of eosinophils
and mast cells.
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